Recruiting PHASE4 INTERVENTIONAL 3-arm
NCT06675851
Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People
Reward-specific Changes of Cerebral Dopamine Synthesis in Healthy Volunteers and Depressed Patients
Sponsor: Austrian Science Fund (FWF)
Conditions
Major Depressive Disorder (MDD)
Interventions
Cipralex (escitalopram) WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline
Updated 1 time since 2024 Last updated: Nov 4, 2024 Started: Dec 1, 2022 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06675851, this PHASE4 trial focuses on Major Depressive Disorder (MDD) and remains actively recruiting participants. Sponsored by Austrian Science Fund (FWF), it has been updated 1 time since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Recruiting — PHASE4
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Austrian Science Fund (FWF)
- Medical University of Vienna
Data source: Medical University of Vienna
For direct contact, visit the study record on ClinicalTrials.gov .